# Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)

> **NCT01896973** · NA · TERMINATED · sponsor: **HistoSonics, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia (BPH)

## Interventions

- **DEVICE:** Vortx Rx - Histotripsy BPH Device

## Key facts

- **NCT ID:** NCT01896973
- **Lead sponsor:** HistoSonics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Study stopped due to business decision
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01896973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01896973, "Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01896973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*